← Back to Search

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by Curium US LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a special injection that helps doctors see prostate cancer cells in patients whose cancer has returned and spread after initial treatments. The injection uses a radioactive substance to make the cancer cells visible in imaging tests.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Adverse Events
Patient-Level Correct Detection Rate (CDR)
Region-Level Correct Localization Rate (CLR)
Secondary study objectives
Score of Image Quality

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic Imaging with 64Cu-PSMA-I&TExperimental Treatment1 Intervention
64Cu-PSMA I\&T
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
64Cu-PSMA I&T
2022
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Curium US LLCLead Sponsor
5 Previous Clinical Trials
1,017 Total Patients Enrolled
2 Trials studying Prostate Cancer
558 Patients Enrolled for Prostate Cancer
~10 spots leftby Dec 2025